Svoronos Dawn — SEC insider filings

SEC reporting owner CIK 1574579. 30 insider filings on record with FilingPulse; latest filed 2026-09-03.

Transaction summary — filings shown

Covers all 30 filings on record, filed 2020-12-11 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Xenon Pharmaceuticals Inc. (XENE)Director8—1 leg · 25,000 sh · $967,50013
ACELYRIN, Inc. (SLRN)Director41 leg · 15,000 sh · $270,000—10
Adverum Biotechnologies, Inc. (ADVM)Director92 legs · 50,000 sh · $225,916—13
Global Blood Therapeutics, Inc. (GBT)Director4—2 legs · 3,517 sh · $110,77615
PTC THERAPEUTICS, INC. (PTCT)Director5—4 legs · 2,119 sh · $83,8304

Insider filings — Svoronos Dawn

FiledFormIssuerReported transactionsSource
2026-09-034Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 5,144 @ $8.15 · Option exercise (M): 5,144 (derivative) @ $0EDGAR
2026-06-034Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 2,645 · Tax withholding (F): 1,416 @ $53.41 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0EDGAR
2025-12-104Adverum Biotechnologies, Inc. (ADVM)Code (U): 5,000 · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · +1 moreEDGAR
2025-06-204Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 10,450 (derivative) @ $0EDGAR
2025-06-064Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0EDGAR
2025-05-234ACELYRIN, Inc. (SLRN)Disposition to issuer (D): 15,000 · Disposition to issuer (D): 92,158 (derivative) · Disposition to issuer (D): 23,243 (derivative) · Disposition to issuer (D): 155,450 (derivative)EDGAR
2024-06-204Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 10,520 (derivative) @ $0EDGAR
2024-06-114ACELYRIN, Inc. (SLRN)Grant/award (A): 92,158 (derivative) @ $0EDGAR
2024-06-054Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 15,542 (derivative) @ $0EDGAR
2023-08-244Xenon Pharmaceuticals Inc. (XENE)Sale (S): 25,000 @ $38.70EDGAR
2023-06-134Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2023-06-024Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 18,475 (derivative) @ $0EDGAR
2023-05-114ACELYRIN, Inc. (SLRN)Purchase (P): 15,000 @ $18 · Other (J): 155,450 (derivative) @ $0 · Other (J): 155,450 (derivative) @ $0 · Other (J): 23,243 (derivative) @ $0 · Other (J): 23,243 (derivative) @ $0EDGAR
2023-05-044ACELYRIN, Inc. (SLRN)Grant/award (A): 23,243 (derivative) @ $0EDGAR
2022-10-064Global Blood Therapeutics, Inc. (GBT)Disposition to issuer (D): 5,376 · Disposition to issuer (D): 3,600 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 5,247 (derivative) · Disposition to issuer (D): 5,600 (derivative) · +1 moreEDGAR
2022-06-294Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 18,000 (derivative) @ $0EDGAR
2022-06-224Global Blood Therapeutics, Inc. (GBT)Sale (S): 1,908 @ $27.24EDGAR
2022-06-164Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 3,600 · Option exercise (M): 3,600 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0EDGAR
2022-06-144Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2022-06-104PTC THERAPEUTICS, INC. (PTCT)Sale (S): 738 @ $27.20EDGAR
2022-05-184Adverum Biotechnologies, Inc. (ADVM)Purchase (P): 30,000 @ $0.85EDGAR
2022-01-114PTC THERAPEUTICS, INC. (PTCT)Sale (S): 510 @ $38.52 · Grant/award (A): 3,200 @ $0 · Grant/award (A): 12,000 (derivative) @ $0EDGAR
2021-06-214Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 3,037 · Sale (S): 1,609 @ $36.54 · Option exercise (M): 3,037 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0EDGAR
2021-06-114PTC THERAPEUTICS, INC. (PTCT)Sale (S): 365 @ $41.88EDGAR
2021-06-034Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2021-05-144Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2021-04-014Adverum Biotechnologies, Inc. (ADVM)Purchase (P): 20,000 @ $10.02EDGAR
2021-02-024PTC THERAPEUTICS, INC. (PTCT)Sale (S): 506 @ $56.96EDGAR
2021-01-084PTC THERAPEUTICS, INC. (PTCT)Grant/award (A): 1,650 @ $0 · Grant/award (A): 10,000 (derivative) @ $0EDGAR
2020-12-114Adverum Biotechnologies, Inc. (ADVM)Grant/award (A): 45,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1574579 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs